Experts’ consensus: pharmaco-invasive therapy for ST‐elevation myocardial infarction along with focus on secondary prevention and cardiac rehabilitation in India

Arup Dasbiswas, Samir Kubba, Jossy Chacko


In India, patients with acute coronary syndrome (ACS) tend to present with higher percentage of ST-elevation myocardial infarction (STEMI). Numerous existing challenges like patient unawareness, lack of structured STEMI care systems, inadequacy of promptly available facilities and unequipped ambulances for patient transport make it difficult to achieve optimal STEMI treatment. Also, due to socio-economic diversities prevailing in India, a large proportion of the entire population has access to only basic primary healthcare and are unable to afford proper medical facilities. Judicious and timely reperfusion strategy has been the mainstay of STEMI management. Even though, percutaneous coronary intervention (PCI) continues to be the gold standard for treating STEMI worldwide, it is not the ideal strategy in many Indian settings, especially in villages and smaller towns/cities. In such scenarios, pharmaco-invasive approach has proved to be a better reperfusion therapeutic strategy for improving treatment outcomes and subsequently reducing morbidity and mortality. The purpose of this consensus article is to highlight the clinical perspectives of Indian cardiologists at identifying and addressing the need gaps currently existing in India for optimization of STEMI treatment approaches. The experts shared their views on the rationale of pharmaco-invasive approach and highlighted the significance of commonly used thrombolytic agents, STEMI treatment protocols, secondary prevention and cardiac rehabilitation.


STEMI, Pharmacoinvasive approach, Reperfusion, Cardiovascular disease, PCI, Acute coronary syndrome

Full Text:



Mc Namara K, Alzubaidi H, Jackson JK. Cardiovascular disease as a leading cause of death: how are pharmacists getting involved? Integr Pharm Res Pract. 2019 Feb 4;8:1-11.

Abdul-Aziz AA, Desikan P, Prabhakaran D. Tackling the Burden of Cardiovascular Diseases in India. Circ Cardiovasc Qual Outcomes. 2019 Apr;12(4):e005195.

Prabhakaran D, Jeemon P, Sharma M. The changing patterns of cardiovascular diseases and their risk factors in the states of India: the Global Burden of Disease Study 1990–2016. Lancet Glob Health. 2018 Dec;6(12):e1339-e1351.

Arora S, Qamar A, Gupta P. Design and rationale of the North Indian ST-Segment Elevation Myocardial Infarction Registry: A prospective cohort study. Clin Cardiol. 2019 Dec;42(12):1140-1146.

Guha S, Sethi R, Ray S. Cardiological Society of India: Position statement for the management of ST elevation myocardial infarction in India. Indian Heart J. 2017 Apr;69 Suppl 1:S63-S97.

STEMI in India, European Heart Journal. 2016;37(31):2449-453.

WHO. Cardiovascular diseases (CVDs) Key facts. Available at Last accessed on on 8th April, 2020.

Alexander T, Juvale NJ, Dasbiswas A. Pharmaco-invasive Therapy with Fibrinolytic Agents: A Potent Lifesaving Reperfusion Strategy in STEMI Patients in Metro/Tier-I Cities in India. J Assoc Physicians India. 2018;66(5):76-82.

Sharma M, Ganguly NK. Premature coronary artery disease in Indians and its associated risk factors. Vasc Health Risk Manag. 2005;1(3):217-225.

Xavier D, Pais P, Devereaux PJ. Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet. 2008;371(9622):1435-42.

Alexander T, Mullasari AS, Kaifoszova Z. Framework for a National STEMI Program: consensus document developed by STEMI INDIA, Cardiological Society of India and Association Physicians of India. Indian Heart J. 2015;67(5):497-502.

Joshi P, Islam S, Pais P. Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA. 2007;297(3):286-94.

Farah A, Barbagelata A. Unmet goals in the treatment of Acute Myocardial Infarction: Review. F1000Res. 2017;6. pii: F1000 Faculty Rev-1243.

V Sharma. Pharmaco-invasive strategy: An attractive alternative for management of ST-elevation myocardial infarction when timely primary percutaneous coronary intervention is not feasible. J Postgrad Med. 2018;64(2):73-74.

Armstrong PW, Gershlick AH, Goldstein P. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013;368(15):1379-87.

Alexander T, Victor SM, Mullasari AS. Protocol for a prospective, controlled study of assertive and timely reperfusion for patients with ST-segment elevation myocardial infarction in Tamil Nadu: the TN-STEMI programme. BMJ Open. 2013 Dec 2;3(12):e003850.

Victor SM, Vijayakumar S, Alexander T. Two-year follow-up data from the STEPP-AMI study: A prospective, observational, multicenter study comparing tenecteplase-facilitated PCI versus primary PCI in Indian patients with STEMI. Indian Heart J. 2016;68(2):169-73.

Chopra HK. Challenges of STEMI care in India & the real world. Indian Heart J. 2015;67(1):15-7.

Capodanno D, Dangas G. Facilitated/pharmaco-invasive approaches in STEMI. Curr Cardiol Rev. 2012;8(3):177-180.

Al Shammeri O, Garcia L. Thrombolysis in the age of Primary Percutaneous Coronary Intervention: Mini-Review and Meta-analysis of Early PCI. Int J Health Sci (Qassim). 2013;7(1):91-100.

ElGuindy AM. STREAM and FAST-MI - Pharmacoinvasive therapy: A continued role for fibrinolysis in the primary PCI era. Glob Cardiol Sci Pract. 2014;2014(2):56-60.

Ali MR, Salim Hossain M, Islam MA et al. Aspect of thrombolytic therapy: a review. Scientific World Journal. 2014;2014:586510.

Bhatia L, Clesham GJ, Turner DR. Clinical implications of ST-segment non-resolution after thrombolysis for myocardial infarction. J R Soc Med. 2004;97(12):566-70.

Hilleman DE, Tsikouris JP, Seals AA. Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007;27(11):1558-70.

Verstraete M. Third-generation thrombolytic drugs. Am J Med. 2000;109(1):52-8.

Dasbiswas A, Hiremath J, Trailokya A. Overview of reteplase, A novel thrombolytic agent in Indian context. Cardiol Pharmacol. 2015;4:136-42.

Dalal JJ, Alexander T, Banerjee PS. 2013 consensus statement for early reperfusion and pharmaco-invasive approach in patients presenting with chest pain diagnosed as STEMI (ST elevation myocardial infarction) in an Indian setting. J Assoc Physicians India. 2014;62(6):473-83.

Simpson D, Siddiqui MA, Scott LJ. Reteplase: a review of its use in the management of thrombotic occlusive disorders. Am J Cardiovasc Drugs. 2006;6(4):265-85.

Xavier AA, Chandana R, Sarwar A. A Comparative Study of Thrombolytics Used for The Treatment of STEMI in a South Indian Tertiary Care Hospital. Research in Pharmacy and Health Sciences. 2016; 2(3):160-162.

Melandri G, Vagnarelli F, Calabrese D. Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56.

Dalal J, Sahoo PK, Singh RK. Role of thrombolysis in reperfusion therapy for management of AMI: Indian scenario. Indian Heart J. 2013;65(5):566-85.

Aslanabadi N, Safaie N, Talebi F. The Streptokinase Therapy Complications and its Associated Risk Factors in Patients with Acute ST Elevation Myocardial Infarction. Iran J Pharm Res. 2018;17(Suppl):53-63.

Xu L, Wang L, Li K. Nicorandil prior to primary percutaneous coronary intervention improves clinical outcomes in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2019;13:1389-1400.

Ishibashi Y, Takahashi N, Tokumaru A. Effects of long-term nicorandil administration on endothelial function, inflammation, and oxidative stress in patients without coronary artery disease. J Cardiovasc Pharmacol. 2008;51(3):311-6.

Ota S, Nishikawa H, Takeuchi M. Impact of nicorandil to prevent reperfusion injury in patients with acute myocardial infarction: Sigmart Multicenter Angioplasty Revascularization Trial (SMART). Circ J. 2006;70(9):1099-104.

Tarkin JM, Kaski JC. Vasodilator Therapy: Nitrates and Nicorandil. Cardiovasc Drugs Ther. 2016;30(4):367-378.

Harari E, Eisen A. Early treatment with high-potency statins in patients with acute coronary syndrome-an example of personalized medicine. J Thorac Dis. 2018;10(Suppl 17):S2062-S2066.

Schwartz GG, Ganz P, Waters D. Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. Am J Cardiol. 2003;92(9):1109-12.

Sun Y, Qi G, Gao Y. Effect of different loading doses of atorvastatin on percutaneous coronary intervention for acute coronary syndromes. Can J Cardiol. 2010;26(9):481-485.

Shah CP, Shah BP, Dani SI. Efficacy and safety of the intensive dose of rosuvastatin 40mg/day in patients with acute coronary syndrome and at high risk of cardiovascular disease-ROSUVEES-2. Indian Heart J. 2016;68(6):766-71.

Stone NJ. Statins in Secondary Prevention: Intensity Matters. J Am Coll Cardiol. 2017;69(22):2707-09.

Wander GS, Jadhav UM, Chemburkar A. Lipid management in India: a nationwide, cross-sectional physician survey. Lipids Health Dis. 2017;16(1):130.

Kikkert WJ, Damman P. Optimal duration of dual antiplatelet therapy for coronary artery disease. Neth Heart J. 2018;26(6):321-33.

Jneid H, Bhatt DL, Corti R. Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. Arch Intern Med. 2003;163(10):1145-53.

Dobesh PP, Oestreich JH. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy. 2014;34(10):1077-090.

Sawhney JPS, Dalal J, Mullasari A. Therapeutic experience of ticagrelor in Indian patients with acute coronary syndrome: A non-interventional, prospective, and observational study. Indian Heart J. 2019;71(4):344-49.

Levy AE, Huang C, Huang A. Recent Approaches to Improve Medication Adherence in Patients with Coronary Heart Disease: Progress Towards a Learning Healthcare System. Curr Atheroscler Rep. 2018;20(1):5.

Mehta S, Granger C, Grines CL et al. Confronting system barriers for ST- elevation MI in low and middle income countries with a focus on India. Indian Heart J. 2018;70(1):185-90.

Johnston S, Brightwell R, Ziman M. Paramedics and pre-hospital management of acute myocardial infarction: diagnosis and reperfusion. Emerg Med J. 2006;23(5):331-34.

Isted A, Williams R, Oakeshott P. Secondary prevention following myocardial infarction: a clinical update. Br J Gen Pract. 2018;68(668):151-52.

Gupta R, Islam S, Mony P. Socioeconomic factors and use of secondary preventive therapies for cardiovascular diseases in South Asia: The PURE study. Eur J Prev Cardiol. 2015;22(10):1261-71.

Dalal HM, Doherty P, Taylor RS. Cardiac rehabilitation. BMJ. 2015;351:h5000.

Ghisi GLM, Contractor A, Abhyankar M. Cardiac rehabilitation knowledge, awareness, and practice among cardiologists in India. Indian Heart J. 2018;70(5):753-55.

Scherrenberg, Martijn, and Paul Dendale. "What is the best way of organizing the follow-up of patients with cardiovascular disease?" European Journal of Preventive Cardiology. 2019;26(18): 1968-970.